Abstract 96P
Background
Determination of MMR functioning in EC is recommended by international guidelines. Its deficiency leads to MSI with intermediate prognosis. Available data have shown a reasonable concordance between IHC-MMR and NGS-MSI. We aim at evaluating the sensitivity and specificity of NGS-MSI obtained from a comprehensive cancer genome profiling (CGP) assay compared with the gold standard IHC-MMR.
Methods
Selected EC patients were profiled using TruSight Oncology500 High Throughput solution. MSI status was determined by 130 noncoding homopolymer regions and at least 40 sites were assessed to provide a score (threshold MSI high>20). IHC-MMR evaluation was collected from standard pathology report.
Results
From March 2022 to May 2023, 404 EC were enrolled. NGS-MSI evaluation was available for 354 (87%; see table). Cohort characteristics are reported in the table. Sensitivity and specificity of NGS-MSI testing compared to IHC-MMR were 99% (n=223/224) and 52% (n= 68/130) respectively, with a concordance rate of 82% (Cohen Kappa = 0.58; p < .0001). The positive predictive value of NGS-MSI was 78% (n=223/285), while the negative predictive value was 99% (n= 68/69). Among the 62 misclassified cases, 19 were MSH6 + MSH2 deficient, 42 MLH1 + PMS2 deficient and 1 was deficient for PMS2, MLH1 and MSH6. 38 MLH1 + PMS2 deficient patients were addressed to MLH1 promoter methylation analysis: results are available for 15 cases (11 hypermethylated, 2 partially hypermethylated). All 19 MSH6 + MSH2 deficient were addressed to genetic counselling: results are available only for 3 patient (1 displaying a MSH2 pathogenic variant). Table: 96P
Characteristics | Cohort (N = 354) | ||
Histotype, n (%) | |||
Endometrioid | 307 (87%) | ||
Serous carcinoma | 18 (5%) | ||
Others | 29 (8%) | ||
FIGO Stage 2019*, n (%) | |||
I-II | 149 (93%) | ||
III-IV | 25 (7%) | ||
MSI status, n (%) | |||
MSI | 69 (19%) | ||
MSS | 285 (81%) | ||
MMR IHC status, n (%) | |||
pMMR | 224 (63%) | ||
dMMR | 130 (37%) |
Conclusions
A moderate concordance between IHC-MMR and NGS-MSI was reported in our study. However, given the approval of immunotherapy in several settings it is important to further characterize the misclassified cases.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Nero: Non-Financial Interests, Personal, Other: Illumina. D. Lorusso: Financial Interests, Personal, Invited Speaker: Clovis, GSK, MSD, AZ, PharmaMar.G. Scambia: Financial Interests, Personal, Invited Speaker: MSD, Clovis, Tesaro, J&J. All other authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract